Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Feb 23 (Reuters) - The attorney general for one of the most populous U.S. states this week urged federal drug regulators to address safety risks associated with the widely used asthma and allergy medicine Singulair, saying current warnings on the drug's packaging are insufficient, particularly for children.
Organon Announces HADLIMA Has Been Selected by the US Department of VA
Organon's Humira biosimilar gets exclusive spot on VA formulary
Organon Co earnings beat by $0.09, revenue topped estimates
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31
Organon’s attempt to revive a once-rejected “natural” contraceptive is over, a spokesperson confirmed to Endpoints News.
Organon`s Biologic Follistim AQ (follitropin) Receives Approval in the U.S.